Tag Archives: Bernstein

Lipitor Lawsuit News: Federal Judicial Panel to Reconsider Consolidation of Lawsuits Alleging an Association Between Lipitor and Diabetes, Bernstein Liebhard LLP Reports

Lipitor Lawsuit News: Federal Judicial Panel to Reconsider Consolidation of Lawsuits Alleging an Association Between Lipitor and Diabetes, Bernstein Liebhard LLP Reports












New York, New York (PRWEB) December 24, 2013

As Lipitor lawsuits (http://www.thelipitorlawsuit.com/) filed on behalf of individuals who allegedly develop new onset-Type 2 diabetes due to their use of the cholesterol-lowering statin continue to mount in courts around the country, Bernstein Liebhard LLP notes that the U.S. Judicial Panel on Multidistrict Litigation (JPML) will once again take up a request from plaintiffs to consolidate federally-filed Lipitor claims in a single jurisdiction for pretrial proceedings. According to court documents, the Panel will hear Oral Arguments on the matter on January 30, 2014, when it convenes its next hearing session in New Orleans, Louisiana. Plaintiffs have asked that the multidistrict litigation for all federal Lipitor lawsuits be established in the U.S. District Court, District of South Carolina, where a number of such claims are already being handled in a consolidated manner. (In re Lipitor (Atorvastatin) Litigation, MDL No. 2502 (JPML))

“Lawsuits alleging a link between the use of Lipitor and diabetes are mounting rapidly in federal courts throughout the U.S. A consolidated proceeding, such as that currently under consideration by the JPML, would provide an efficient means of litigating these claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Lipitor lawsuit consultations to anyone who may have developed Type 2 diabetes due to the use of this statin medication.

Lipitor and Diabetes Allegations

According to court documents, Lipitor lawsuits involving diabetes allegations have been mounting since February 2012, when the U.S. Food & Drug Administration (FDA) ordered Pfizer, Inc. to add new warnings to the Lipitor label regarding an increased risk of new-onset diabetes in patients who took the medication. Among other things, these claims allege that Pfizer failed to provide patients and doctors with adequate warnings regarding this risk, and that even the cautions that have been added to the Lipitor label remain inadequate. Plaintiffs further allege that Pfizer marketed Lipitor as safe and effective for years, despite its knowledge of data tying its use to elevated blood glucose levels and the development of Type 2 diabetes.

In July, the JPML rejected a previous request from plaintiffs to consolidate federally-filed Lipitor lawsuits in a single jurisdiction, holding that there were too few filings to justify such a proceeding. However, according to a second petition filed by plaintiffs in October, more than 100 Lipitor lawsuits involving diabetes allegations are now pending in federal courts throughout the country. Despite the mounting claims, court documents indicate that Pfizer is still opposed to the creation of a multidistrict litigation for these lawsuits.

A multidistrict litigation like the one proposed for Lipitor lawsuits preserves the resources of the court, parties and witnesses, and would likely avoid duplicative discovery and inconsistent court rulings across a large number of cases involving similar allegations of fact. Among other things, such a proceeding would allow all federally-filed claims involving Lipitor and diabetes to undergo coordinated pretrial proceedings, including discovery and motions practice.

Individuals who allegedly developed Type 2 diabetes after they began taking Lipitor may be entitled to compensation for medical bills, lost wages, pain and suffering, and more. Find out more about filing a Lipitor lawsuit at Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the Plaintiffs Hot List, recognizing the top plaintiffs firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.thelipitorlawsuit.com/

https://plus.google.com/115936073311125306742?rel=author
























Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.









Pradaxa Lawsuits Move Forward, as Federal Judge Considers New Sanctions Against Boehringer, Bernstein Liebhard LLP Reports

Pradaxa Lawsuits Move Forward, as Federal Judge Considers New Sanctions Against Boehringer, Bernstein Liebhard LLP Reports












New York, NY (PRWEB) December 24, 2013

Thousands of Pradaxa lawsuits (http://www.pradaxalawsuithelp.com/ ) continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of Illinois, Bernstein Liebhard LLP reports. According to an Order issued on December 18, 2013, U.S. District Judge David R. Herndon is considering new sanction against defendant, Boehringer Ingelheim, and suggested that the company acted “unreasonably, negligently, willfully, and in bad faith,” in regards to certain evidence it now says it is unable to provide in accordance with an earlier directive from the Court. According to Judge Herndon’s Order, the sanctions will be determined once Bellwether Discovery has ended in the Pradaxa litigation, and could affect a number of aspects, including Boehringer Ingelheim’s ability to use certain affirmative defenses. (In Re: Pradaxa (Dabigatran Etexilate) Products Liability Litigation – MDL No. 2385)

“We are watching the Pradaxa litigation very closely, as we continue to investigate claims on behalf of alleged victims of the drug’s bleeding side effects. The final decision on these sanctions could have a significant impact on the outcome of Pradaxa lawsuits,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Pradaxa lawsuit evaluations to individuals who suffered serious internal bleeding while using this medication.

Pradaxa Lawsuits

Court documents indicate that just over 2,000 Pradaxa lawsuits have been filed in the Southern District of Illinois. All of the claims allege that Boehringer Ingelheim failed to provide adequate warnings regarding the risk of Pradaxa bleeding side effects, as well as the lack of an effective antidote for such an occurrence. The litigation’s first bellwether trial is scheduled to begin in August 2014.

According to court records, Judge Herndon has already sanctioned Boehringer Ingelheim once before for failing to preserve numerous documents sought by plaintiffs with cases pending in the proceeding. According to an Order dated December 9th, the company was fined $ 931,000 after Judge Herndon determined that the steps it had taken to preserve the documents in question were “grossly inadequate” and that the company had “made misrepresentations” regarding its efforts.

Pradaxa is a blood thinner that was brought to market in October 2010, and is used to prevent strokes in people with atrial fibrillation. According to Pradaxa lawsuits, the medication was marketed as a superior alternative to warfarin, a blood thinner that has been in use for decades. However, these claims point out that while the internal bleeding that is sometimes associated with warfarin can be stopped via the administration of vitamin K, there is no readily-available antidote for similar occurrences related to the use of Pradaxa.

A study released in October by the Institute for Safe Medicine Practices revealed that in 2012, Pradaxa had been named in more adverse event reports than any other drug monitored by the U.S. Food & Drug Administration (FDA). The 3,200 reports of Pradaxa side effects received that year included 582 that involved a patient death. By contrast, warfarin was the subject of just 861 FDA adverse reports that included 56 deaths.*

Alleged victims of Pradaxa bleeding side effects may be entitled to compensation for medical bills, lost wages, pain and suffering, and other injury-related damages. To learn more please visit Bernstein Liebhard LLP’s website. For a free case review, please call 800-511-5092.

*ismp.org/QuarterWatch/pdfs/2012Q4.pdf, ISMP, October 17, 2013

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info (at) consumerinjurylawyers (dot) com

http://www.pradaxalawsuithelp.com/

https://plus.google.com/115936073311125306742?rel=author
























Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.









As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Finding that Acetaminophen Combined With Alcohol May Increase Risk for Kidney Damage

As Tylenol Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Finding that Acetaminophen Combined With Alcohol May Increase Risk for Kidney Damage












New York, NY (PRWEB) December 25, 2013

As Tylenol lawsuits (http://www.tylenollawsuitclaims.com/) continue to mount in courts around the country, Bernstein Liebhard LLP notes that a new study has found that taking acetaminophen in combination with even small amounts of alcohol may be associated with an increased risk for kidney damage. According to a report from HealthDay News, the study, which was presented last month at the American Public Health Association’s annual meeting in Boston, looked at data from more than 10,000 people who had been surveyed about their alcohol consumption, use of acetaminophen and health problems. Almost half of the respondents who reported combining acetaminophen with alcohol also reported kidney dysfunction. *

“Dozens of lawsuits are now pending in federal court that allege a link between the use of Tylenol and liver damage. This study is just a further reminder that the acetaminophen in these over-the-counter medications can often be associated with very serious side effects,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free legal reviews to individuals who may have suffered liver damage resulting in hospitalization, liver transplantation, or death, allegedly associated with the use of a Tylenol-brand medication.

Tylenol and Liver Damage

According to court documents, at least 100 Tylenol lawsuits alleging acetaminophen can cause liver damage, even when taken as directed, are currently pending in a multidistrict litigation now underway in U.S. District Court, Eastern District of Pennsylvania. All of these lawsuits similarly allege that Johnson & Johnson failed to provide consumers with adequate warnings about the potential effects of acetaminophen use on the liver, including liver failure and the need for a liver transplant. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)

According to the U.S. Food & Drug Administration (FDA), acetaminophen was the leading cause of acute liver failure in the U.S. between 1998 and 2003. From 1990 to 1998, acetaminophen was blamed for 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths annually. Two years ago, the FDA reduced the amount of acetaminophen that prescription drugs can contain to 325 milligrams per two pills. **

Johnson & Johnson announced over the summer it was adding more prominent, red-lettered warnings to the labels of Tylenol products regarding the potential for severe liver damage. According to a report from Bloomberg.com, Extra Strength Tylenol – which contains 500 milligrams of acetaminophen per tablet – was to appear with the warnings in October. The modified labels will begin appearing on other Tylenol-brand medications in the coming months.***

Individuals who suffered acetaminophen-induced liver damage resulting in hospitalization, liver transplantation or death allegedly associated with a Tylenol product may be entitled to compensation for medical expenses and other injury-related damages. Find out more about filing a Tylenol lawsuit by visiting Bernstein Liebhard LLP’s website. For a free evaluation of your claim, please call 800-511-5092.

*consumer.healthday.com/diseases-and-conditions-information-37/misc-kidney-problem-news-432/tylenol-alcohol-a-bad-mix-says-study-681768.html, HealthDay News, November 4, 2013

**fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm239894.htm, FDA, January 2011

***bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013

About Bernstein Liebhard LLP

Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.

Bernstein Liebhard LLP

10 East 40th Street

New York, New York 10016

800-511-5092

ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:

Felecia L. Stern, Esq.

Bernstein Liebhard LLP

info(at)consumerinjurylawyers(dot)com

http://www.tylenollawsuitclaims.com/

https://plus.google.com/115936073311125306742?rel=author
























Vocus©Copyright 1997-

, Vocus PRW Holdings, LLC.
Vocus, PRWeb, and Publicity Wire are trademarks or registered trademarks of Vocus, Inc. or Vocus PRW Holdings, LLC.